The 2024 Nobel Prize in Chemistry was recently granted to David Baker, Demis Hassabis and John M. Jumper, renowned for their pioneering works in protein design.

Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...

Structure Therapeutics’ lead drug candidate is chasing big pharmaceutical rivals in the race for new oral weight-loss medications, and the company had been telling investors to expect data late this ...

Sept 29 (Reuters) - Shares of Structure Therapeutics (GPCR.O), opens new tab soared 70% on Friday to hit the highest levels since their debut on the Nasdaq as early data from the drug developer's oral ...

Eli Lilly is casting a long shadow over the GLP-1 market. Structure Therapeutics linked its oral candidate to significant reductions in blood sugar and weight in a phase 2a trial on Monday, only for ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...